NCT00046787已完成2 期
Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 19
研究概览
简要总结
The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed recurrent small cell lung cancer.
- •One prior treatment of chemotherapy.
- •At least three weeks since last chemotherapy treatment and recovery from any related side effects.
- •At least three weeks since last chest radiotherapy and at least 10 days since head irradiation and recovery from acute side effects.
- •At least one target tumor less than or equal to 20 mm (or less than or equal to 10 mm on spiral CT-scan).
- •If a patient has had previous documented Central Nervous System (CNS) involvement, only controlled disease is acceptable.
排除标准
- •Superior vena cava syndrome.
研究者
研究点 (19)
Loading locations...
相似试验
已完成
2 期
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian CancerOvarian NeoplasmsNCT00046800Astellas Pharma Inc80
已完成
2 期
The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric CancerStomach NeoplasmsNCT01531452Chinese Academy of Medical Sciences43
招募中
2 期
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT06341296West China Hospital86
终止
2 期
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721IgANLNC3GMNNCT02682407Omeros Corporation31
已完成
2 期
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian CancerCancerOvarian CancerNCT00523380Novo Nordisk A/S10